还没做过化疗，EGFR是野生型的病友一定要去做ALK的检测

jzjqian 发表于 2012-7-25 15:45

9 `4 [5 f4 l3 g' ]) H) d                               
登录/注册后可看大图

7 J$ Q" q  Z! }请教，像我这样的，手术22个月了，还能去原手术医院拿到病理作EGFR检查么？

可以，但要有针对性，

请问，肺鳞癌，只做过一次化疗，骨髓抑制严重，后吃特罗凯4个月基本无效，可以参加实验组吗？

不可以了,要没做过任何治疗的,包括化疗和靶向药

Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  


+ U  p$ W' l* ]5 E4 S, a9 PSub-category:
Molecular Targets


Category:
Tumor Biology
: m+ w( D4 g5 M- G- l' m$ f6 w  k
; z  H# g6 V# K: t# ?- y
Meeting:
2011 ASCO Annual Meeting
& ]2 G6 R  f! p4 n" e9 D% W9 V
6 n: u  x2 K/ p7 S0 f
: ^: U: ^7 x$ ~6 K% ASession Type and Session Title:
Poster Discussion Session, Tumor Biology
1 {$ a! E& }1 i/ _+ q  u) ?* Q

Abstract No:
10517
0 S0 U& Q9 H( n# X; Y: p

6 J  u9 ?% M$ g7 wCitation:
6 G( @6 M9 P6 {, W) D8 d7 UJ Clin Oncol 29: 2011 (suppl; abstr 10517)


/ j! X8 [9 X' `* Z8 A/ F" a" EAuthor(s):
! C) B) E  V$ d7 h$ uJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China



0 p( \8 i$ e! P; T+ WAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
# x- Q, Q" c0 q) p3 |5 l$ x- b$ X. E
Abstract Disclosures
+ n1 z+ V: x5 ^; H3 _# h) {
Abstract:

% X8 v; [( _/ I2 p' v
+ g" c( B8 C# l& V/ }Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
) C" V5 H) l  x$ s, h

: }, n3 Q* T8 K

由吴一龙教授牵头的A80810029临床试验上周启动，初诊未治疗的晚期肺腺癌患者检测到ALK阳性，可参加一线crizotinib 对比力比泰+卡铂的临床研究，药物全部免费，即使分配到力比泰组，疾病进展之后可免费获得crizotinib.

没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

boeun 发表于 2012-11-18 16:37

                               
登录/注册后可看大图

* M: I- e5 m# i8 @  t2 }! ^4 t/ n没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

化疗过的没机会了

平安！ 发表于 2012-7-20 11:20

                               
登录/注册后可看大图

6 ]5 @, A0 M: z: m易瑞沙、特罗凯有效的病人基本上可以断定ALK（-）。极其罕见EGFR、ALK同时突变的。
ALK一个指标医院要900多 ...

4 E' s7 Z2 i) y9 X1 A平安，真的没有希望吗？我弟弟虽然特罗凯有效，但是ＥＧＦＲ是野生型，不是突变啊。有没有必要去检测ＡＬＫ呢？
6 U% I' R6 G  p# Z  w
现在病情进展，快没招儿了。

好像想加入挺困难的

小地方没条件做啊